Biotech Values

[jq1234]

IPH.PA: Bad reporting there and by MS analyst as well citing high numbers of grade 3/4 AEs from ph1 dose escalation trial and no ORR. Most of those AEs are from mostly mild to moderate transient infusion and skin reactions. This often happens for mAbs in ph1 oncology trial. Since they are transient, premedication often decrease/reduce large number of cases. Note, few of those grade 3/4 AEs were classified as SAEs.

As of no ORR, what can I say? Do people read carefully before they write? The study included mostly patients who had experienced CR/PR by previous treatments!

Actual poster in link: https://twitter.com/jq1234t/status/605388603166982144